Researchers from Air Force Medical University Provide Details of New Studies and Findings in the Area of Bladder Cancer (Pax2 Mediated Upregulation of Espl1 Contributes To Cisplatin Resistance In Bladder Cancer Through Activating the Jak2/stat3...).

A study conducted in Shannxi, People's Republic of China, focused on the role of Extra spindle-polar body like 1 (ESPL1) in bladder cancer progression and cisplatin resistance. The researchers found that ESPL1 was highly expressed in bladder cancer tumor tissues and cells, particularly in cisplatin-resistant tissues or cells. They also discovered that PAX2-mediated ESPL1 transcriptional activation contributed to cisplatin resistance by activating the JAK2/STAT3 pathway. Silencing ESPL1 or combining it with cisplatin treatment inhibited tumor growth in a xenograft tumor model. This study provides insights into potential therapeutic targets for bladder cancer treatment. [Extracted from the article]